The majority of weight loss from GLP-1 medication is from fat loss, and not muscle loss, new evidence suggests.

A study published by Danish researchers on Friday suggests that semaglutide drugs like Wegovy and Ozempic can significantly ...

U.S. President Donald Trump announced on Friday that the federal government is taking steps to expand access to GLP-1 ...

Starting July 2026, Medicare will begin a temporary 'GLP-1 Bridge' program offering limited coverage of weight loss drugs like Wegovy and Zepbound for certain retirees. Applicants must have Part D or ...

Doctronic reports new AI analysis reveals GLP-1 medications may cause underreported symptoms like menstrual irregularities ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...

Hershey's gum and mint sales are rising as GLP-1 weight-loss drug users seek relief from side effects like 'Ozempic breath'.

A sweeping meta-analysis of 36 studies has found that GLP-1-based weight loss treatments primarily reduce fat mass while largely preserving lean muscle. The findings counter earlier fears that such ...

While GLP-1 medications first gained visibility for diabetes care and later for weight loss, researchers are now evaluating ...

"There was a pendulum that swung that was so body acceptance, positivity, everybody be who they want to be. And now it's ...

GLP-1 overdoses are on the rise, and some clinicians suggest informing patients of the risk in the initial consultation.

The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.